FDA First Amendment Litigation: Will Amarin Case Break The Log Jam?
This article was originally published in The Pink Sheet Daily
Executive Summary
Courts have issued mixed rulings in cases challenging FDA restrictions on drug promotion, but with oral arguments set for July 7, Amarin’s suit could provide a definitive answer on what companies can tell physicians.